1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Acumen Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) sabirnetug, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Acumen Pharmaceuticals | 542 | 2024-02-29 | 2025-10-27 |
Alzheimer Disease (1) · Cognitive Dysfunction (1) · Memory Disorders (1)
Canada (1) · Germany (1) · Spain (1) · United Kingdom (1) · United States (1)
2023 (1)